Literature DB >> 30712478

Development and validation of the Gestalt Therapy Fidelity Scale.

Madeleine Fogarty1, Sunil Bhar1, Stephen Theiler1.   

Abstract

Objective: Three studies were conducted to develop and validate the Gestalt Therapy Fidelity Scale (GTFS), a 21-item measure of treatment adherence for Gestalt Therapy (GT).Method: Thirty five items for possible inclusion in the GTFS were generated on the basis of a literature review. In Study 1, a Delphi methodology consulting 63 international GT experts was used to select items for the GTFS. In Study 2, six experts used the scale to rate video-based sessions of GT, and provided feedback on the usability of the scale. In Study 3, 176 participants from 18 countries used the GTFS to rate GT and not-GT video recorded sessions.
Results: The Delphi study consensus method resulted in 25 items for consideration in the GTFS. The scoring system and items were subsequently revised following further feedback from experts (Study 2). The GTFS was found to significantly discriminate between GT and not-GT based sessions (Study 3): raters scored GT sessions significantly higher than not-GT sessions. High levels of internal and inter-rater reliability were found.
Conclusion: The GTFS is supported as a psychometrically sound measure of treatment adherence for GT, and hence can be used to assess the degree to which therapists are administering GT.

Entities:  

Keywords:  Gestalt therapy; psychoanalytic/psychodynamic therapy; test development; treatment fidelity

Mesh:

Year:  2019        PMID: 30712478     DOI: 10.1080/10503307.2019.1571688

Source DB:  PubMed          Journal:  Psychother Res        ISSN: 1050-3307


  1 in total

1.  A Single-Case Design Investigation for Measuring the Efficacy of Gestalt Therapy to Treat Depression in Older Adults with Dementia in Italy and in Mexico: A Research Protocol.

Authors:  Alessandra Merizzi; Rosanna Biasi; José Fernando Álvarez Zamudio; Margherita Spagnuolo Lobb; Mirko Di Rosa; Sara Santini
Journal:  Int J Environ Res Public Health       Date:  2022-03-10       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.